Celecoxib exacerbates hepatic fibrosis and induces hepatocellular necrosis in rats treated with porcine serum

Prostaglandins and Other Lipid Mediators

Volumn 88, Issue 3-4, 2009, Pages 63-67

  Liu, Hao ^a,b   Wei, Wei ^a   Li, Xiang ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b BENGBU MEDICAL COLLEGE   (China)

Author keywords

Celecoxib; Liver fibrosis; PGE2; Porcine serum

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; PROSTAGLANDIN E2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DISEASE EXACERBATION; DRUG INDUCED DISEASE; ENZYME INHIBITION; HISTOPATHOLOGY; LIVER FIBROSIS; LIVER NECROSIS; MALE; NONHUMAN; PROSTAGLANDIN BLOOD LEVEL; PROSTAGLANDIN SYNTHESIS INHIBITION; RAT; SERUM; TISSUE SECTION;

ANIMALS; BODY WEIGHT; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; LIVER; LIVER CIRRHOSIS; LIVER DISEASES; MALE; NECROSIS; ORGAN SIZE; PYRAZOLES; RANDOM ALLOCATION; RATS; RATS, WISTAR; SERUM; SULFONAMIDES; SWINE;

EID: 63149124347     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2008.10.002     Document Type: Article

References (27)

1. Suleyman H., Demircan B., and Karagoz Y. Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol Rep 59 (2007) 247-258
2. Ueno N., Takegoshi Y., Kamei D., et al. Coupling between cyclooxygenases and terminal prostanoid synthases. Biochem Biophys Res Commun 338 (2005) 70-76
3. Harris R.C., and Breyer M.D. Update on cyclooxygenase-2 inhibitors. Clin J Am Soc Nephrol 1 (2006) 236-245
4. Yin H., Cheng L., Langenbach R., et al. Prostaglandin I(2) and E(2) mediate the protective effects of cyclooxygenase-2 in a mouse model of immune-mediated liver injury. Hepatology 45 (2007) 159-169
5. Treffkorn L., Scheibe R., Maruyama T., et al. PGE2 exerts its effect on the LPS-induced release of TNF-alpha, ET-1, IL-1alpha IL-6 and IL-10 via the EP2 and EP4 receptor in rat liver macrophages. Prostag Other Lipid Mediat 74 (2004) 113-123
6. Flisiak R., and Prokopowicz D. One year follow-up of patients treated with misoprostol in acute phase of viral hepatitis B. Prostag Other Lipid Mediat 60 (2000) 161-165
7. Williams G.W. An update on nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors. Curr Pain Headache Rep 9 (2005) 377-389
8. Buttgereit F., Burmester G.R., and Simon L.S. Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors. Am J Med 110 Suppl. 3A (2001) 13S-19S
9. Hiratsuka T., and Sakamoto C. The choice of selective COX-2 inhibitors. Nippon Rinsho 65 (2007) 1819-1823
10. Ong M.M., Wang A.S., Leow K.Y., et al. Nimesulide-induced hepatic mitochondrial injury in heterozygous Sod2(+/-) mice. Free Radic Biol Med 40 (2006) 420-429
11. Stadlmann S., Zoller H., Vogel W., et al. COX-2 inhibitor (nimesulide) induced acute liver failure. Virchows Arch 440 (2002) 553-555
12. Ramos S.G., Montenegro A.P., Goissis G., et al. Captopril reduces collagen and mast cell and eosinophil accumulation in pig serum-induced rat liver fibrosis. Pathol Int 44 (1994) 655-661
13. Hui A.Y., Leung W.K., Chan H.L., et al. Effect of celecoxib on experimental liver fibrosis in rat. Liver Int 26 (2006) 125-136
14. Xu H.M., Wei W., Jia X.Y., et al. Effects and mechanisms of total glucosides of paeony on adjuvant arthritis in rats. J Ethnopharmacol 109 (2007) 442-448
15. Kankuri E., Vaali K., Korpela R., et al. Effects of a COX-2 preferential agent nimesulide on TNBS-induced acute inflammation in the gut. Inflammation 25 (2001) 301-310
16. Heer P., Sandel M.H., Guertens G., et al. Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer. Cancer Chemother Pharmacol 62 5 (2008) 811-819
17. Baba Y., Saeki K., Onodera T., et al. Serological and immunohistochemical studies on porcine-serum-induced hepatic fibrosis in rats. Exp Mol Pathol 79 (2005) 229-235
18. Tsukamoto H., Matsuoka M., and French S.W. Experimental models of hepatic fibrosis: a review. Semin Liver Dis 10 (1990) 56-65
19. Bhunchet E., and Fujieda K. Capillarization and venularization of hepatic sinusoids in porcine serum-induced rat liver fibrosis: a mechanism to maintain liver blood flow. Hepatology 18 (1993) 1450-1458
20. Chamouard P., Walter P., Baumann R., et al. Prolonged cholestasis associated with short-term use of celecoxib. Gastroenterol Clin Biol 29 (2005) 1286-1288
21. Bykov I.L., Palmen M., Rainsford K.D., et al. Chronic effects of celecoxib, a cyclooxygenase-2 inhibitor, cause enhanced alcohol-induced liver steatosis in rats. Inflammopharmacology 14 (2006) 36-41
22. Gilroy D.W., and Colville-Nash P.R. New insights into the role of COX 2 in inflammation. J Mol Med 78 (2000) 121-129
23. Reilly T.P., Brady J.N., Marchick M.R., et al. A protective role for cyclooxygenase-2 in drug-induced liver injury in mice. Chem Res Toxicol 14 (2001) 1620-1628
24. Peltekian K.M., Makowka L., Williams R., et al. Prostaglandins in liver failure and transplantation: regeneration, immunomodulation, and cytoprotection. Prostaglandins in Liver Transplantation Research Group. Liver Transpl Surg 2 (1996) 171-184
25. Hossain M.A., Wakabayashi H., Izuishi K., et al. The role of prostaglandins in liver ischemia-reperfusion injury. Curr Pharm Des 12 (2006) 2935-2951
26. Quiroga J., and Prieto J. Liver cytoprotection by prostaglandins. Pharmacol Ther 58 1 (1993) 67-91
27. Flisiak R., and Prokopowicz D. Effect of misoprostol on the course of viral hepatitis B. Hepatogastroenterology 44 (1997) 1419-1425